Skip to main content
Erschienen in: Inflammation 1/2012

01.02.2012

Stimulation of FasL Induces Production of Proinflammatory Mediators Through Activation of Mitogen-Activated Protein Kinases and Nuclear Factor-κB in THP-1 Cells

verfasst von: Sang-Min Lee, Eun-Ju Kim, Kyoungho Suk, Won-Ha Lee

Erschienen in: Inflammation | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

FasL is a member of the tumor necrosis factor (TNF) superfamily involved in the various immune reactions such as activation-induced cell death, cytotoxic effector function, and establishment of immune privileged sites through its interaction with Fas. On the other hand, FasL is known to transmit a reverse signal that serves as a T cell co-stimulatory signal. However, the role of FasL-mediated reverse signaling in macrophage function has not been investigated. In order to investigate the presence of FasL-mediated signaling in macrophages, the human macrophage-like cell line THP-1 was analyzed after treatment with FasL ligating agents such as recombinant Fas:Fc fusion protein or anti-FasL monoclonal antibody. Stimulation of FasL induced the expression of proinflammatory mediators such as matrix metalloproteinase-9, TNF-α, and IL-8. The specificity of the reaction was confirmed by the transfection of the FasL-specific siRNAs, which suppressed FasL expression as well as the production of proinflammatory mediators. Utilization of various inhibitors of signaling adaptors and ELISA-base nuclear factor (NF)-κB binding assay demonstrated that the signaling initiated from FasL is mediated by mitogen-activated protein kinases including extracellular signal-regulated kinase, p38, and c-Jun N-terminal kinase which induce subsequent activation of NF-κB. These data indicate that membrane expression of FasL and its interaction with its counterpart may contribute to the inflammatory activation of macrophages during immune reactions or pathogenesis of chronic inflammatory diseases.
Literatur
1.
Zurück zum Zitat Chen, N.J., M.W. Huang, and S.L. Hsieh. 2001. Enhanced secretion of IFN-gamma by activated Th1 cells occurs via reverse signaling through TNF-related activation-induced cytokine. Journal of Immunology 166: 270–276. Chen, N.J., M.W. Huang, and S.L. Hsieh. 2001. Enhanced secretion of IFN-gamma by activated Th1 cells occurs via reverse signaling through TNF-related activation-induced cytokine. Journal of Immunology 166: 270–276.
2.
Zurück zum Zitat van Essen, D., H. Kikutani, and D. Gray. 1995. CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature 378: 620–623.PubMedCrossRef van Essen, D., H. Kikutani, and D. Gray. 1995. CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature 378: 620–623.PubMedCrossRef
3.
Zurück zum Zitat Cerutti, A., A. Schaffer, R.G. Goodwin, S. Shah, H. Zan, S. Ely, and P. Casali. 2000. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD + IgM + B cells. Journal of Immunology 165: 786–794. Cerutti, A., A. Schaffer, R.G. Goodwin, S. Shah, H. Zan, S. Ely, and P. Casali. 2000. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD + IgM + B cells. Journal of Immunology 165: 786–794.
4.
Zurück zum Zitat Zhang, J., T.W. Salcedo, X. Wan, S. Ullrich, B. Hu, T. Gregorio, P. Feng, S. Qi, H. Chen, Y.H. Cho, Y. Li, P.A. Moore, and J. Wu. 2001. Modulation of T-cell responses to alloantigens by TR6/DcR3. Journal of Clinical Investigation 107: 1459–1468.PubMedCrossRef Zhang, J., T.W. Salcedo, X. Wan, S. Ullrich, B. Hu, T. Gregorio, P. Feng, S. Qi, H. Chen, Y.H. Cho, Y. Li, P.A. Moore, and J. Wu. 2001. Modulation of T-cell responses to alloantigens by TR6/DcR3. Journal of Clinical Investigation 107: 1459–1468.PubMedCrossRef
5.
Zurück zum Zitat Chou, A.H., H.F. Tsai, L.L. Lin, S.L. Hsieh, P.I. Hsu, and P.N. Hsu. 2001. Enhanced proliferation and increased IFN-gamma production in T cells by signal transduced through TNF-related apoptosis-inducing ligand. Journal of Immunology 167: 1347–1352. Chou, A.H., H.F. Tsai, L.L. Lin, S.L. Hsieh, P.I. Hsu, and P.N. Hsu. 2001. Enhanced proliferation and increased IFN-gamma production in T cells by signal transduced through TNF-related apoptosis-inducing ligand. Journal of Immunology 167: 1347–1352.
6.
Zurück zum Zitat Suzuki, I., and P.J. Fink. 2000. The dual functions of fas ligand in the regulation of peripheral CD8+ and CD4+ T cells. Proceedings of the National Academy of Sciences of the United States of America 97: 1707–1712.PubMedCrossRef Suzuki, I., and P.J. Fink. 2000. The dual functions of fas ligand in the regulation of peripheral CD8+ and CD4+ T cells. Proceedings of the National Academy of Sciences of the United States of America 97: 1707–1712.PubMedCrossRef
7.
Zurück zum Zitat Bae, E.M., W.J. Kim, K. Suk, Y.M. Kang, J.E. Park, W.Y. Kim, E.M. Choi, B.K. Choi, B.S. Kwon, and W.H. Lee. 2008. Reverse signaling initiated from GITRL induces NF-kappaB activation through ERK in the inflammatory activation of macrophages. Molecular Immunology 45: 523–533.PubMedCrossRef Bae, E.M., W.J. Kim, K. Suk, Y.M. Kang, J.E. Park, W.Y. Kim, E.M. Choi, B.K. Choi, B.S. Kwon, and W.H. Lee. 2008. Reverse signaling initiated from GITRL induces NF-kappaB activation through ERK in the inflammatory activation of macrophages. Molecular Immunology 45: 523–533.PubMedCrossRef
8.
Zurück zum Zitat Jeon, S.T., W.J. Kim, S.M. Lee, M.Y. Lee, S.B. Park, S.H. Lee, I.S. Kim, K. Suk, B.K. Choi, E.M. Choi, B.S. Kwon, and W.H. Lee. 2010. Reverse signaling through BAFF differentially regulates the expression of inflammatory mediators and cytoskeletal movements in THP-1 cells. Immunology and Cell Biology 88: 148–156.PubMedCrossRef Jeon, S.T., W.J. Kim, S.M. Lee, M.Y. Lee, S.B. Park, S.H. Lee, I.S. Kim, K. Suk, B.K. Choi, E.M. Choi, B.S. Kwon, and W.H. Lee. 2010. Reverse signaling through BAFF differentially regulates the expression of inflammatory mediators and cytoskeletal movements in THP-1 cells. Immunology and Cell Biology 88: 148–156.PubMedCrossRef
9.
Zurück zum Zitat Lee, S.M., S.T. Jeon, W.J. Kim, K. Suk, and W.H. Lee. 2010. Macrophages express membrane bound form of APRIL that can generate immunomodulatory signals. Immunology 131: 350–356.PubMedCrossRef Lee, S.M., S.T. Jeon, W.J. Kim, K. Suk, and W.H. Lee. 2010. Macrophages express membrane bound form of APRIL that can generate immunomodulatory signals. Immunology 131: 350–356.PubMedCrossRef
10.
Zurück zum Zitat Lettau, M., M. Paulsen, D. Kabelitz, and O. Janssen. 2009. FasL expression and reverse signalling. Results and Problems in Cell Differentiation 49: 49–61.PubMedCrossRef Lettau, M., M. Paulsen, D. Kabelitz, and O. Janssen. 2009. FasL expression and reverse signalling. Results and Problems in Cell Differentiation 49: 49–61.PubMedCrossRef
11.
Zurück zum Zitat Krammer, P.H., R. Arnold, and I.N. Lavrik. 2007. Life and death in peripheral T cells. Nature Reviews. Immunology 7: 532–542.PubMedCrossRef Krammer, P.H., R. Arnold, and I.N. Lavrik. 2007. Life and death in peripheral T cells. Nature Reviews. Immunology 7: 532–542.PubMedCrossRef
12.
Zurück zum Zitat Brunner, T., C. Wasem, R. Torgler, I. Cima, S. Jakob, and N. Corazza. 2003. Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Seminars in Immunology 15: 167–176.PubMedCrossRef Brunner, T., C. Wasem, R. Torgler, I. Cima, S. Jakob, and N. Corazza. 2003. Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Seminars in Immunology 15: 167–176.PubMedCrossRef
13.
Zurück zum Zitat Igney, F.H., and P.H. Krammer. 2005. Tumor counterattack: fact or fiction? Cancer Immunology, Immunotherapy 54: 1127–1136.PubMedCrossRef Igney, F.H., and P.H. Krammer. 2005. Tumor counterattack: fact or fiction? Cancer Immunology, Immunotherapy 54: 1127–1136.PubMedCrossRef
14.
Zurück zum Zitat Niederkorn, J.Y. 2006. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nature Immunology 7: 354–359.PubMedCrossRef Niederkorn, J.Y. 2006. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nature Immunology 7: 354–359.PubMedCrossRef
15.
Zurück zum Zitat Suzuki, I., and P.J. Fink. 1998. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. The Journal of Experimental Medicine 187: 123–128.PubMedCrossRef Suzuki, I., and P.J. Fink. 1998. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. The Journal of Experimental Medicine 187: 123–128.PubMedCrossRef
16.
Zurück zum Zitat Suzuki, I., S. Martin, T.E. Boursalian, C. Beers, and P.J. Fink. 2000. Fas ligand costimulates the in vivo proliferation of CD8+ T cells. Journal of Immunology 165: 5537–5543. Suzuki, I., S. Martin, T.E. Boursalian, C. Beers, and P.J. Fink. 2000. Fas ligand costimulates the in vivo proliferation of CD8+ T cells. Journal of Immunology 165: 5537–5543.
17.
Zurück zum Zitat Desbarats, J., R.C. Duke, and M.K. Newell. 1998. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Natural Medicines 4: 1377–1382.CrossRef Desbarats, J., R.C. Duke, and M.K. Newell. 1998. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Natural Medicines 4: 1377–1382.CrossRef
18.
Zurück zum Zitat Sun, M., S. Lee, S. Karray, M. Levi-Strauss, K.T. Ames, and P.J. Fink. 2007. Cutting edge: two distinct motifs within the Fas ligand tail regulate Fas ligand-mediated costimulation. Journal of Immunology 179: 5639–5643. Sun, M., S. Lee, S. Karray, M. Levi-Strauss, K.T. Ames, and P.J. Fink. 2007. Cutting edge: two distinct motifs within the Fas ligand tail regulate Fas ligand-mediated costimulation. Journal of Immunology 179: 5639–5643.
19.
Zurück zum Zitat Sun, M., K.T. Ames, I. Suzuki, and P.J. Fink. 2006. The cytoplasmic domain of Fas ligand costimulates TCR signals. Journal of Immunology 177: 1481–1491. Sun, M., K.T. Ames, I. Suzuki, and P.J. Fink. 2006. The cytoplasmic domain of Fas ligand costimulates TCR signals. Journal of Immunology 177: 1481–1491.
20.
Zurück zum Zitat Sun, M., and P.J. Fink. 2007. A new class of reverse signaling costimulators belongs to the TNF family. Journal of Immunology 179: 4307–4312. Sun, M., and P.J. Fink. 2007. A new class of reverse signaling costimulators belongs to the TNF family. Journal of Immunology 179: 4307–4312.
21.
Zurück zum Zitat Izawa, K., J. Kitaura, Y. Yamanishi, T. Matsuoka, A. Kaitani, M. Sugiuchi, M. Takahashi, A. Maehara, Y. Enomoto, T. Oki, T. Takai, and T. Kitamura. 2009. An activating and inhibitory signal from an inhibitory receptor LMIR3/CLM-1: LMIR3 augments lipopolysaccharide response through association with FcRgamma in mast cells. Journal of Immunology 183: 925–936.CrossRef Izawa, K., J. Kitaura, Y. Yamanishi, T. Matsuoka, A. Kaitani, M. Sugiuchi, M. Takahashi, A. Maehara, Y. Enomoto, T. Oki, T. Takai, and T. Kitamura. 2009. An activating and inhibitory signal from an inhibitory receptor LMIR3/CLM-1: LMIR3 augments lipopolysaccharide response through association with FcRgamma in mast cells. Journal of Immunology 183: 925–936.CrossRef
22.
Zurück zum Zitat Lee, S.M., Y.P. Nam, K. Suk, and Lee WH. 2010. Immune receptor expressed on myeloid cells 1 (IREM-1) inhibits B cell activation factor (BAFF)-mediated inflammatory regulation of THP-1 cells through modulation of the activities of extracellular regulated kinase (ERK). Clinical & Experimental Immunology 161: 504–511.CrossRef Lee, S.M., Y.P. Nam, K. Suk, and Lee WH. 2010. Immune receptor expressed on myeloid cells 1 (IREM-1) inhibits B cell activation factor (BAFF)-mediated inflammatory regulation of THP-1 cells through modulation of the activities of extracellular regulated kinase (ERK). Clinical & Experimental Immunology 161: 504–511.CrossRef
23.
Zurück zum Zitat Xi, H., K.J. Katschke Jr., K.Y. Helmy, P.A. Wark, N. Kljavin, H. Clark, J. Eastham-Anderson, T. Shek, M. Roose-Girma, N. Ghilardi, and M. van Lookeren Campagne. 2010. Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. The Journal of Experimental Medicine 207(7–16): S1–S5. Xi, H., K.J. Katschke Jr., K.Y. Helmy, P.A. Wark, N. Kljavin, H. Clark, J. Eastham-Anderson, T. Shek, M. Roose-Girma, N. Ghilardi, and M. van Lookeren Campagne. 2010. Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. The Journal of Experimental Medicine 207(7–16): S1–S5.
24.
Zurück zum Zitat Chong, Z.Z., and K. Maiese. 2007. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histology and Histopathology 22: 1251–1267.PubMed Chong, Z.Z., and K. Maiese. 2007. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histology and Histopathology 22: 1251–1267.PubMed
25.
Zurück zum Zitat Lorenz, U. 2009. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunological Reviews 228: 342–359.PubMedCrossRef Lorenz, U. 2009. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunological Reviews 228: 342–359.PubMedCrossRef
26.
Zurück zum Zitat Bonny, C., A. Oberson, S. Negri, C. Sauser, and D.F. Schorderet. 2001. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 50: 77–82.PubMedCrossRef Bonny, C., A. Oberson, S. Negri, C. Sauser, and D.F. Schorderet. 2001. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 50: 77–82.PubMedCrossRef
27.
Zurück zum Zitat Rosenau, C., D. Emery, B. Kaboord, and M.W. Qoronfleh. 2004. Development of a high-throughput plate-based chemiluminescent transcription factor assay. Journal of Biomolecular Screening 9: 334–342.PubMedCrossRef Rosenau, C., D. Emery, B. Kaboord, and M.W. Qoronfleh. 2004. Development of a high-throughput plate-based chemiluminescent transcription factor assay. Journal of Biomolecular Screening 9: 334–342.PubMedCrossRef
28.
Zurück zum Zitat Lee, W.H., S.H. Kim, Y. Lee, B.B. Lee, B. Kwon, H. Song, B.S. Kwon, and J.E. Park. 2001. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arteriosclerosis, Thrombosis, and Vascular Biology 21: 2004–2010.PubMedCrossRef Lee, W.H., S.H. Kim, Y. Lee, B.B. Lee, B. Kwon, H. Song, B.S. Kwon, and J.E. Park. 2001. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arteriosclerosis, Thrombosis, and Vascular Biology 21: 2004–2010.PubMedCrossRef
29.
Zurück zum Zitat Kim, W.J., and W.H. Lee. 2004. LIGHT is expressed in foam cells and involved in destabilization of atherosclerotic plaques through induction of matrix metalloproteinase-9 and IL-8. Immune Network 4: 116–122. Kim, W.J., and W.H. Lee. 2004. LIGHT is expressed in foam cells and involved in destabilization of atherosclerotic plaques through induction of matrix metalloproteinase-9 and IL-8. Immune Network 4: 116–122.
30.
Zurück zum Zitat Guha, M., and N. Mackman. 2001. LPS induction of gene expression in human monocytes. Cellular Signalling 13: 85–94.PubMedCrossRef Guha, M., and N. Mackman. 2001. LPS induction of gene expression in human monocytes. Cellular Signalling 13: 85–94.PubMedCrossRef
31.
Zurück zum Zitat Hu, X., L.C. Moscinski, N.I. Valkov, A.B. Fisher, B.J. Hill, and K.S. Zuckerman. 2000. Prolonged activation of the mitogen-activated protein kinase pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line. Cell Growth & Differentiation 11: 191–200. Hu, X., L.C. Moscinski, N.I. Valkov, A.B. Fisher, B.J. Hill, and K.S. Zuckerman. 2000. Prolonged activation of the mitogen-activated protein kinase pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line. Cell Growth & Differentiation 11: 191–200.
32.
Zurück zum Zitat Requena, P., A. Daddaoua, E. Guadix, A. Zarzuelo, M.D. Suarez, F. Sanchez de Medina, and O. Martinez-Augustin. 2009. Bovine glycomacropeptide induces cytokine production in human monocytes through the stimulation of the MAPK and the NF-kappaB signal transduction pathways. British Journal of Pharmacology 157: 1232–1240.PubMedCrossRef Requena, P., A. Daddaoua, E. Guadix, A. Zarzuelo, M.D. Suarez, F. Sanchez de Medina, and O. Martinez-Augustin. 2009. Bovine glycomacropeptide induces cytokine production in human monocytes through the stimulation of the MAPK and the NF-kappaB signal transduction pathways. British Journal of Pharmacology 157: 1232–1240.PubMedCrossRef
33.
Zurück zum Zitat Yang, Y., N. Lu, J. Zhou, Z.N. Chen, and P. Zhu. 2008. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 47: 1299–1310.CrossRef Yang, Y., N. Lu, J. Zhou, Z.N. Chen, and P. Zhu. 2008. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 47: 1299–1310.CrossRef
34.
Zurück zum Zitat Ballif, B.A., A. Shimamura, E. Pae, and J. Blenis. 2001. Disruption of 3-phosphoinositide-dependent kinase 1 (PDK1) signaling by the anti-tumorigenic and anti-proliferative agent N-alpha-tosyl-l-phenylalanyl chloromethyl ketone. The Journal of Biological Chemistry 276: 12466–12475.PubMedCrossRef Ballif, B.A., A. Shimamura, E. Pae, and J. Blenis. 2001. Disruption of 3-phosphoinositide-dependent kinase 1 (PDK1) signaling by the anti-tumorigenic and anti-proliferative agent N-alpha-tosyl-l-phenylalanyl chloromethyl ketone. The Journal of Biological Chemistry 276: 12466–12475.PubMedCrossRef
35.
Zurück zum Zitat Han, Y., J.A. Englert, R. Yang, R.L. Delude, and M.P. Fink. 2005. Ethyl pyruvate inhibits nuclear factor-κB-dependent signaling by directly targeting p65. The Journal of Pharmacology and Experimental Therapeutics 312: 1097–1105.PubMedCrossRef Han, Y., J.A. Englert, R. Yang, R.L. Delude, and M.P. Fink. 2005. Ethyl pyruvate inhibits nuclear factor-κB-dependent signaling by directly targeting p65. The Journal of Pharmacology and Experimental Therapeutics 312: 1097–1105.PubMedCrossRef
36.
Zurück zum Zitat Wahl, C., S. Liptay, G. Adler, and R.M. Schmid. 1998. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. Journal of Clinical Investigation 101: 1163–1174.PubMedCrossRef Wahl, C., S. Liptay, G. Adler, and R.M. Schmid. 1998. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. Journal of Clinical Investigation 101: 1163–1174.PubMedCrossRef
37.
Zurück zum Zitat Fenteany, G., and M. Glogauer. 2004. Cytoskeletal remodeling in leukocyte function. Current Opinion in Hematology 11: 15–24.PubMedCrossRef Fenteany, G., and M. Glogauer. 2004. Cytoskeletal remodeling in leukocyte function. Current Opinion in Hematology 11: 15–24.PubMedCrossRef
38.
Zurück zum Zitat May, R.C., and L.M. Machesky. 2001. Phagocytosis and the actin cytoskeleton. Journal of Cell Science 114: 1061–1077.PubMed May, R.C., and L.M. Machesky. 2001. Phagocytosis and the actin cytoskeleton. Journal of Cell Science 114: 1061–1077.PubMed
39.
Zurück zum Zitat Alvarez-Errico, D., H. Aguilar, F. Kitzig, T. Brckalo, J. Sayos, and M. Lopez-Botet. 2004. IREM-1 is a novel inhibitory receptor expressed by myeloid cells. European Journal of Immunology 34: 3690–3701.PubMedCrossRef Alvarez-Errico, D., H. Aguilar, F. Kitzig, T. Brckalo, J. Sayos, and M. Lopez-Botet. 2004. IREM-1 is a novel inhibitory receptor expressed by myeloid cells. European Journal of Immunology 34: 3690–3701.PubMedCrossRef
40.
Zurück zum Zitat Sui, L., N. Li, Q. Liu, W. Zhang, T. Wan, B. Wang, K. Luo, H. Sun, and X. Cao. 2004. IgSF13, a novel human inhibitory receptor of the immunoglobulin superfamily, is preferentially expressed in dendritic cells and monocytes. Biochemical and Biophysical Research Communications 319: 920–928.PubMedCrossRef Sui, L., N. Li, Q. Liu, W. Zhang, T. Wan, B. Wang, K. Luo, H. Sun, and X. Cao. 2004. IgSF13, a novel human inhibitory receptor of the immunoglobulin superfamily, is preferentially expressed in dendritic cells and monocytes. Biochemical and Biophysical Research Communications 319: 920–928.PubMedCrossRef
41.
Zurück zum Zitat Chung, D.H., M.B. Humphrey, M.C. Nakamura, D.G. Ginzinger, W.E. Seaman, and M.R. Daws. 2003. CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation. Journal of Immunology 171: 6541–6548. Chung, D.H., M.B. Humphrey, M.C. Nakamura, D.G. Ginzinger, W.E. Seaman, and M.R. Daws. 2003. CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation. Journal of Immunology 171: 6541–6548.
42.
Zurück zum Zitat Alvarez-Errico, D., J. Sayos, and M. Lopez-Botet. 2007. The IREM-1 (CD300f) inhibitory receptor associates with the p85alpha subunit of phosphoinositide 3-kinase. Journal of Immunology 178: 808–816. Alvarez-Errico, D., J. Sayos, and M. Lopez-Botet. 2007. The IREM-1 (CD300f) inhibitory receptor associates with the p85alpha subunit of phosphoinositide 3-kinase. Journal of Immunology 178: 808–816.
Metadaten
Titel
Stimulation of FasL Induces Production of Proinflammatory Mediators Through Activation of Mitogen-Activated Protein Kinases and Nuclear Factor-κB in THP-1 Cells
verfasst von
Sang-Min Lee
Eun-Ju Kim
Kyoungho Suk
Won-Ha Lee
Publikationsdatum
01.02.2012
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 1/2012
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-010-9283-3

Weitere Artikel der Ausgabe 1/2012

Inflammation 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.